COVID-19 May Increase IVIG-Resistance in Kids Prior to Developing Kawasaki Disease
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease
Measles: A Physician’s Perspective
George Rust, MD, MPH, joined the faculty of the Florida State University (FSU) College of Medicine in 2016 and serves as medical director for six local county public health department. He is the author of a 2025 measles fact sheet to help address this important public health concern.
Activating B Cells Key to TIL Cancer Therapy Effectiveness
Researchers at Moffitt Cancer Center have found that tapping into the body’s own immune system and activating a type of immune cell known as B cells could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy.
FDA Approves Gammagard Liquid ERC to Treat PI, Plans to Discontinue Gammagard SD in December 2027
The U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for individuals 2 years of age and older with primary immunodeficiency (PI).
Update on Measles
Once eradicated in the U.S., measles is now on the rise due to a growing mistrust of public health guidance, but it is highly preventable with vaccination.
Vaccine Advisers Recommend New RSV Vaccine for Infants
A group of outside advisers to the Centers for Disease Control and Prevention (CDC) voted 5-2 to recommend the use of Merck’s new antibody vaccine, Enflonsia (clesrovimab), that can protect babies from respiratory syncytial virus (RSV).
Flebogamma (IVIG) Effective in Treating Post-Polio Syndrome
Grifols announced positive results from its Phase II/III clinical trial evaluating the efficacy and safety of Flebogamma 5% DIF (intravenous immune globulin [IVIG]) to treat patients with post-polio syndrome, which demonstrated a significant improvement in distance walked compared to placebo.
FDA Approves Immune Checkpoint Inhibitor for Head and Neck Cancer
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) to treat patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (combined positive score [CPS] ≥1) as determined by an FDA-approved test.
IVIG Effectively Increased Platelet Counts in Maternal Thrombocytopenia
A recent study that sought to evaluate the efficacy of intravenous immune globulin (IVIG) and identify predictors of platelet response in pregnant persons with moderate-to-severe thrombocytopenia, as well as to optimize clinical decisions and resource use, has found that IVIG effectively increases platelet counts.
FDA Approves Alzheimer’s Blood Test
The U.S. Food and Drug Administration has given marketing clearance to the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, a blood test to help diagnose Alzheimer’s disease for adults 55 and older who are showing signs and symptoms of the disease. It is the first test to be approved to aid in the early detection of the disease in the United States.